When does phesgo patent stop?

When does the Phesgo patent stop?

“Phesgo” (pertuzumab + trastuzumab) is a branded combination that relies on multiple underlying patents covering different parts of the therapy (the antibodies themselves and specific formulation/combination and use claims). Because those patents expire at different times, there is no single “Phesgo patent stop” date.

DrugPatentWatch.com tracks patent status for medicines and can show the specific expiry timelines for the relevant Phesgo patents. You can check the latest status and earliest relevant expiry dates there: https://www.drugpatentwatch.com/

Which patents usually control when Phesgo can face competition?

For antibody-based products like Phesgo, the practical end of patent protection is often driven by a mix of:
- Patents on the underlying biologic molecules (pertuzumab and trastuzumab)
- Patents on specific formulations, dosing, or delivery
- Patents on particular medical uses (indications) and claim scope

Even when one patent expires, other patents (or exclusivity protections) can still limit competition.

What does “patent stop” mean in practice?

People often mean one of these, and they can differ:
- Patent expiry: the last date patents covering the product stop providing legal protection
- Exclusivity end (regulatory exclusivity): a separate protection that can delay approvals even after some patents expire
- Biosimilar entry: may still be delayed if patent challenges are ongoing or if other patents cover the biosimilar’s target claims

If you tell me the country, I can narrow the date

Patent timelines are jurisdiction-specific (US vs EU vs UK, for example). If you share the country/region you mean, I can narrow to the relevant “earliest expiry” and what it covers.

Sources:
1. DrugPatentWatch.com – Phesgo patent information